A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Amphotericin B (AmBisome)

Lipid-based Polyene Antifungal class · 5 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval1992-04-29
Generic availableYes · 5 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$39,114 in CY2024 Part D spend208 claims · 78 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
658 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Amphotericin B used for?

Amphotericin B is a Lipid-based Polyene Antifungal medication tracked in Medicare Part D.

Is there a generic for Amphotericin B?

Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Amphotericin B?

NADAC pricing data not currently available for this drug.

Is Amphotericin B on the FDA shortage list?

Amphotericin B has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Lipid-based Polyene Antifungal1 alternative in D1
01
Amphotericin B Liposome
Lipid-based Polyene Antifungal
Lowest NADAC
0Generic mfrs
$3.7MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.